Scholarlink

Background <p>Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs.</p> Methods <p>mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2’s association with prognosis and clinicopathological features.</p> Results <p>Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05–0.54; <i>p</i> = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08–0.91; <i>p</i> = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.</p> Conclusions <p>MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Expression and prognostic value of MCM2 in type B thymomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月3日

查看全文
  • Xin Du,
  • Jian Cui,
  • Xintao Yu,
  • Dingfang Cao,
  • Ying Zhang,
  • Lei Yu,
  • Shanqing Li

摘要

Background

Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs.

Methods

mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2’s association with prognosis and clinicopathological features.

Results

Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05–0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08–0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.

Conclusions

MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.